Iovance Biotherapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 557

Market Cap: $3.4B

Website: http://www.iovance.com

Introduction: Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Clinical Trials

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Phase 1

Recruiting

Conditions: Unresectable Melanoma
Metastatic Melanoma
Ocular Melanoma

Interventions: Biological: IOV-3001

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 42

Registration Number: NCT06940739

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma
Soft Tissue Sarcoma
Ewing Sarcoma
Primary Central Nervous System Carcinoma
Melanoma

Interventions: Biological: LN-145/LN-144

First Posted Date: 2024-08-22

Last Posted Date: 2025-04-25

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 40

Registration Number: NCT06566092

Locations: 🇺🇸
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Biological: Lifileucel

First Posted Date: 2024-07-01

Last Posted Date: 2025-03-18

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 60

Registration Number: NCT06481592

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
MD Anderson Cancer Center - U of Texas, Houston, Texas, United States

and more 4 locations

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Phase 3

Recruiting

Conditions: Melanoma
Unresectable Melanoma
Metastatic Melanoma

Interventions: Biological: Lifileucel plus Pembrolizumab
Biological: Pembrolizumab with Optional Crossover Period

First Posted Date: 2023-02-14

Last Posted Date: 2025-04-20

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 670

Registration Number: NCT05727904

Locations: 🇺🇸
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 66 locations

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Conditions: Unresectable Melanoma
Metastatic Melanoma

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-28

Lead Sponsor: Iovance Biotherapeutics, Inc.

Registration Number: NCT05398640

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

and more 16 locations

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Phase 1

Recruiting

Conditions: Unresectable Melanoma
Stage III Non-small Cell Lung Cancer
Metastatic Melanoma
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: IOV-4001

First Posted Date: 2022-05-04

Last Posted Date: 2024-12-05

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 53

Registration Number: NCT05361174

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States

and more 7 locations

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Phase 2

Recruiting

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Biological: LN-145

First Posted Date: 2020-11-03

Last Posted Date: 2025-04-09

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 170

Registration Number: NCT04614103

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 57 locations

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Biological: IOV-2001
Drug: IL-2
Drug: Low dose IL-2
Drug: High dose IL-2

First Posted Date: 2019-11-07

Last Posted Date: 2025-03-20

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 7

Registration Number: NCT04155710

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸
Baptist Cancer Center, Memphis, Tennessee, United States

and more 4 locations

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck
Metastatic Melanoma
Non-small Cell Lung Cancer

Interventions: Biological: Lifileucel
Biological: LN-145-S1
Biological: LN-145
Drug: Pembrolizumab
Drug: Ipilimumab
Drug: Nivolumab-relatlimab
Drug: Nivolumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-Paclitaxel
Drug: Pemetrexed

First Posted Date: 2018-08-24

Last Posted Date: 2025-04-09

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 245

Registration Number: NCT03645928

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇬🇧
The Royal Marsden NHS Foundation Trust, London, England, United Kingdom
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 42 locations

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: LN-145
Drug: Durvalumab

First Posted Date: 2018-02-05

Last Posted Date: 2019-04-16

Lead Sponsor: Iovance Biotherapeutics, Inc.

Registration Number: NCT03419559

Locations: 🇺🇸
UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
University of California San Diego, Moores Cancer Center, La Jolla, California, United States

and more 5 locations

Home Terms & Conditions Privacy Policy